Daiwa Securities Group Portfolio holdings
AUM
$27.1B
1-Year Return
23.24%
This Quarter Return
+13.09%
1 Year Return
+23.24%
3 Year Return
+64.59%
5 Year Return
+118.48%
10 Year Return
+210.79%
AUM
$12.9B
AUM Growth
+$1.9B
(+17%)
Cap. Flow
+$468M
Cap. Flow
% of AUM
3.62%
Top 10 Holdings %
Top 10 Hldgs %
34.89%
Holding
1,326
New
146
Increased
499
Reduced
419
Closed
56
Top Buys
| 1 |
Americold
COLD
|
+$172M |
| 2 |
Omega Healthcare
OHI
|
+$109M |
| 3 |
Sun Communities
SUI
|
+$103M |
| 4 |
Weyerhaeuser
WY
|
+$101M |
| 5 |
AIRC
Apartment Income REIT Corp.
AIRC
|
+$97.3M |
Top Sells
| 1 |
Equinix
EQIX
|
+$250M |
| 2 |
Kilroy Realty
KRC
|
+$68.5M |
| 3 |
Prologis
PLD
|
+$66.9M |
| 4 |
Welltower
WELL
|
+$66.1M |
| 5 |
STOR
STORE Capital Corporation
STOR
|
+$63.6M |
Sector Composition
| 1 | Real Estate | 60.69% |
| 2 | Technology | 7.51% |
| 3 | Communication Services | 3.67% |
| 4 | Healthcare | 3.56% |
| 5 | Consumer Discretionary | 3.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
976
Acadia Pharmaceuticals
ACAD
$4.02B
| $16K | ﹤0.01% |
299
-590
| -66% | -$31.6K |
|
977
BridgeBio Pharma
BBIO
$10.1B
| $16K | ﹤0.01% |
231
-466
| -67% | -$32.3K |
|
978
Adaptive Biotechnologies
ADPT
$1.89B
| $15K | ﹤0.01% |
257
-466
| -64% | -$27.2K |
|
979
Arrowhead Research
ARWR
$3.99B
| $15K | ﹤0.01% |
193
-388
| -67% | -$30.2K |
|
980
Fate Therapeutics
FATE
$115M
| $15K | ﹤0.01% |
164
-326
| -67% | -$29.8K |
|
|
ALLK
981
DELISTED
Allakos
ALLK
| $14K | ﹤0.01% |
99
-176
| -64% | -$24.9K |
|
982
argenx
ARGX
$46.7B
| $14K | ﹤0.01% |
47
-103
| -69% | -$30.7K |
|
983
Kodiak Sciences
KOD
$513M
| $14K | ﹤0.01% |
95
-151
| -61% | -$22.3K |
|
984
Zai Lab
ZLAB
$3.16B
| $14K | ﹤0.01% |
105
-200
| -66% | -$26.7K |
|
|
XLRN
985
DELISTED
Acceleron Pharma Inc.
XLRN
| $14K | ﹤0.01% |
113
-225
| -67% | -$27.9K |
|
986
HF Sinclair
DINO
$9.57B
| $13K | ﹤0.01% |
504
| – | – |
|
987
Iovance Biotherapeutics
IOVA
$861M
| $13K | ﹤0.01% |
276
-543
| -66% | -$25.6K |
|
988
Novavax
NVAX
$1.29B
| $13K | ﹤0.01% |
+120
| New | +$13K |
|
989
Outfront Media
OUT
$3.12B
| $13K | ﹤0.01% |
672
| – | – |
|
990
United Therapeutics
UTHR
$17.9B
| $13K | ﹤0.01% |
84
-164
| -66% | -$25.4K |
|
|
SYNH
991
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $13K | ﹤0.01% |
196
-390
| -67% | -$25.9K |
|
992
First Horizon
FHN
$11.5B
| $12K | ﹤0.01% |
945
+620
| +191% | +$7.87K |
|
993
Twist Bioscience
TWST
$1.46B
| $12K | ﹤0.01% |
85
-148
| -64% | -$20.9K |
|
|
BPMC
994
DELISTED
Blueprint Medicines
BPMC
| $12K | ﹤0.01% |
105
-204
| -66% | -$23.3K |
|
995
Canadian Imperial Bank of Commerce
CM
$73.3B
| $12K | ﹤0.01% |
270
+110
| +69% | +$4.89K |
|
996
Exelixis
EXEL
$10.1B
| $12K | ﹤0.01% |
583
-1,164
| -67% | -$24K |
|
|
CLPR
997
Clipper Realty
CLPR
$69.8M
| $11K | ﹤0.01% |
1,568
| – | – |
|
998
Amicus Therapeutics
FOLD
$2.45B
| $11K | ﹤0.01% |
490
-948
| -66% | -$21.3K |
|
999
TechnipFMC
FTI
$16.8B
| $11K | ﹤0.01% |
1,629
| – | – |
|
1000
Halozyme
HALO
$8.87B
| $11K | ﹤0.01% |
254
-515
| -67% | -$22.3K |
|